BAX at a glance
Baxter International (BAX, SEC CIK 10456) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 19, 2026 and Form 4 insider filings as recently as September 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Baxter International (BAX) reported revenue of $11.2 billion (up 5.7% from FY2024) and a net loss of $957.0 million. Diluted EPS was -$1.87.
- As of September 30, 2026, 41 institutional investment managers tracked by SignalX reported holding Baxter International (BAX) shares worth $5.0 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $11.2B
- +5.7% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 41 funds
- $5.0B · +2 vs prior quarter
- Latest 8-K
- Nov 19, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: diversified healthcare products including IV solutions, infusion systems, parenteral nutrition, surgical and respiratory devices
- New segment structure: three reportable segments as of Q3 2023; Medical Products & Therapies, Healthcare Systems & Technologies, Pharmaceuticals
- Strategic shift: completed sale of Kidney Care business for $3.71B net proceeds and BioPharma Solutions for $3.96B, focusing on streamlined operations
- Debt reduction: repaid $3.81B legacy debt primarily from Kidney Care sale and additional repayments using BioPharma sale proceeds
- Geographic footprint: products manufactured in 20+ countries and sold in 100+ countries, reinforcing global healthcare access
Risk Factors
- FDA warning letters dated 07/25/2023 and prior, highlighting regulatory compliance risks impacting product approvals and operations
- Exposure to global economic conditions and inflation adversely affecting operations with no mitigation timeline specified
- Supply chain disruptions including manufacturing, sterilization, and distribution difficulties causing product availability risks
- Competition risk from technology advances and changing consumer preferences potentially impairing new product monetization
- Significant indebtedness requiring substantial cash flow allocation for debt service, limiting growth strategy and R&D investments
Management Discussion & Analysis
- Kidney Care business sold for $3.80B cash, net after-tax proceeds approx. $3.3B completed Jan 31, 2025
- Legacy indebtedness of $3.81B repaid in 2025, excluding $2.00B repaid from new notes offering
- Kidney Care segment results reported as discontinued operations, prior periods restated accordingly
- Cost restructuring initiated due to dis-synergies from reduced company size post-sale
- No explicit revenue, profitability, or forward guidance disclosed in provided text
AI summary of the BAX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to risk factors disclosed in Baxter’s 2025 Annual Report
Management Discussion & Analysis
- Revenue $2.976B, up $141M from $2.835B YoY, with Medical Products & Therapies strongest at 6% growth
- Gross margin 33.4% vs 33.5% YoY, excluding special items down 1.1 percentage points
- Advanced Surgery best-performing line, sales up 12%; Other sales weakest, $68M vs $85M YoY
- Operating cash flow $1.07B vs $355M YoY; debt repayments $600M and capital expenditures $363M
- Outlook: tariffs, supply constraints, inflation and geopolitical uncertainty remain headwinds; no meaningful Novum LVP sales during shipment holds
AI summary of the BAX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Investor presentation shared with certain stockholders beginning November 19, 2026
- Reg FD disclosure signals ongoing shareholder engagement, potentially addressing strategy or investor concerns
Item EX-99.1: Item EX-99.1
- FY2026 organic sales growth guidance raised to 3%-4%, versus GAAP sales growth guidance of 4%-5%
- Free cash flow reached $705 million through September 30, 2026, supporting balance-sheet repair
Item 8.01: Other Events
- Quarterly cash dividend maintained at $0.01 per share
- January 4, 2027 payment date for shareholders of record November 27, 2026
Item EX-99.1: Item EX-99.1
- Q3 sales $2.98B, up 5% reported and organically, with growth across all segments and divisions
- GAAP diluted EPS $0.57 versus $(0.10) last year, while adjusted EPS fell 16% to $0.58
Item 2.02: Results of Operations and Financial Condition
- Earnings release covers the quarter ended September 30, 2026
- Exhibit 99.1 contains Baxter’s financial results and management commentary
Item EX-99.1: Item EX-99.1
- John Rogers appointed CFO effective October 1, 2026, replacing the current finance leadership
- Medtech finance executive brings transformation experience from Smith+Nephew and WPP
Item 5.02: Departure/Appointment of Directors or Principal Officers
- John Rogers appointed CFO effective October 1, 2026, following leadership roles at Smith+Nephew and WPP
- CFO compensation includes $925,000 salary, 100% target bonus, and $4,000,000 annual equity target
Item 7.01: Regulation FD Disclosure
- CFO appointment of Mr. Rogers announced on August 19, 2026
- Leadership change potentially affects capital allocation, financial reporting and investor communications
AI summaries of BAX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BAX
Don't miss the next BAX filing
- Alerts as it files. A push when BAX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BAX, by share count.
- Ask anything. An AI agent that reads every BAX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Foster Julie | F | Sep 2, 2026 | 2,098 | $25.70 |
| Hider Andrew P. | F | Sep 2, 2026 | 54,276 | $25.70 |
| Teaff James | F | Sep 1, 2026 | 750 | $25.48 |
| Wallace Steven P. | F | Jun 2, 2026 | 153 | $18.68 |
| Teaff James | F | Jun 2, 2026 | 321 | $18.68 |
| Zielinski Anita A | A | Jun 1, 2026 | 13,426 | - |
| Ampofo William A. II | A | May 5, 2026 | 12,836 | - |
| Craig Jeffrey A | A | May 5, 2026 | 12,836 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $10.6B | $11.2B |
| Gross Profit | $5.0B | $4.0B | $3.4B |
| Operating Income | - | $14.0M | -$308.0M |
| Net Income | $2.7B | -$649.0M | -$957.0M |
| Gross Margin | - | 37.5% | 30.1% |
| Op. Margin | - | 0.1% | -2.7% |
| Net Margin | - | -6.1% | -8.5% |
| Balance Sheet | |||
| Total Assets | $28.3B | $25.8B | $20.1B |
| Equity | - | $7.0B | $6.1B |
| ROE | - | -9.3% | -15.6% |
| Per Share | |||
| EPS | $5.25 | $-1.27 | $-1.87 |
| Cash Flow | |||
| Operating CF | - | $1.0B | $845.0M |
Source: XBRL data in Baxter International (BAX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate BAX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 41 | $5.00B |
| Q2 2026 | 39 | $5.78B |
| Q1 2026 | 37 | $4.34B |
| Q4 2025 | 36 | $4.91B |
| Q3 2025 | 38 | $5.52B |
| Q2 2025 | 38 | $7.41B |
| Q1 2025 | 35 | $5.25B |
| Q4 2024 | 32 | $3.97B |
- Citadel Advisors LLC+4.76M (+2136%)
- AQR Capital Management+4.62M (+239%)
- Morgan Stanley+1.40M (+22%)
- Ameriprise Financial+1.14M (+268%)
- Citigroup+595.8K (+89%)
- BlackRock−16.30M (-20%)
- Bank of America Corp−1.60M (-26%)
- Goldman Sachs Group−1.39M (-19%)
- Invesco Ltd−1.06M (-9%)
- Dimensional Fund Advisors−677.8K (-12%)
- Two Sigma Investments+57.4K
- Citizens Financial Group+18.5K
- Marex Group plc+9.4K
- FMR LLC (Fidelity)−53.91M
Source: 13F-HR filings on SEC EDGAR (aggregated from 296 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BAX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 19, 2026 | - | Analysis | - |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 10-Q | Oct 29, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 8-K | Aug 19, 2026 | - | Analysis | - |
| 8-K | Aug 18, 2026 | - | Analysis | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 14, 2026 | - | Analysis | - |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 8-K | May 8, 2026 | - | Analysis | |
| 4 | May 7, 2026 | - | - | |
| 4 | May 7, 2026 | - | - | |
| 4 | May 7, 2026 | - | - | |
| 4 | May 7, 2026 | - | - | |
| 4 | May 7, 2026 | - | - | |
| 4 | May 7, 2026 | - | - | |
| 4 | May 7, 2026 | - | - | |
| 4 | May 7, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- SKIN · Beauty Health CoSurgical & Medical Instruments & Apparatus
BAX SEC filings: frequently asked questions
Which institutions hold BAX stock?
As of September 30, 2026, the largest Baxter International (BAX) holders among the 13F filers tracked by SignalX were BlackRock ($1.6 billion), Vanguard Capital Management LLC ($813.7 million), Vanguard Portfolio Management LLC ($562.0 million), State Street Corp ($495.2 million), Invesco Ltd ($271.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BAX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Baxter International (BAX) reported revenue of $11.2 billion (up 5.7% from FY2024) and a net loss of $957.0 million. Diluted EPS was -$1.87. The figures come from the XBRL data in the 10-K.
What are the main risks in BAX's latest 10-K?
In the 10-K filed February 12, 2026, Baxter International (BAX) flagged: FDA warning letters dated 07/25/2023 and prior, highlighting regulatory compliance risks impacting product approvals and operations. Exposure to global economic conditions and inflation adversely affecting operations with no mitigation timeline specified. (AI summary of the Risk Factors section.)
What did BAX report in its latest 8-K?
Baxter International (BAX) filed an 8-K on November 19, 2026 reporting Item 7.01 (Regulation FD Disclosure). Investor presentation shared with certain stockholders beginning November 19, 2026.
What are the latest BAX SEC filings?
Baxter International (BAX) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 19, 2026 and a Form 4 insider filing on September 3, 2026.
What is BAX's SEC CIK number?
Baxter International (BAX)'s SEC Central Index Key (CIK) is 10456. EDGAR lists every BAX filing under that number.
Ask anything about BAX
The research agent reads BAX's filings, financials, insider trades and 13F holders, then answers with sources.